Successful Interim Futility Analysis In P3 Trial for GVHD
Filed with ASX · · 3 pages · English
In the deck
Story so far
Earlier from Mesoblast
- MSB Japan Strategy Highlighted At Business Council Meeting
- Mesoblast Phase 2 Diabetic Kidney Disease Results Published
- Preliminary Final Report (Including Appendix 4E)
- MSB Strengthens US Patent Portfolio For Rheumatic Diseases
- Mesoblast P2 Results Show Dose-Related Improvements In RA
Later from Mesoblast
- First Quarter Results On Form 6K
- MD Anderson and NIH Fund Trial Using Mesoblast Technologies
- Mesoblast And Mallinckrodt Enter Into Agreement
- Mesoblast Director Recognized For Cardiovascular Leadership
- Published Results Show MSB Cells Effective In RA Model
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast